Literature DB >> 20026211

Behavioral effects of neuropeptides in rodent models of depression and anxiety.

Susan Rotzinger1, David A Lovejoy, Laura A Tan.   

Abstract

In recent years, studies have advocated neuropeptide systems as modulators for the behavioral states found in mood disorders such as depression and anxiety disorders. Neuropeptides have been tested in traditional animal models and screening procedures that have been validated by known antidepressants and anxiolytics. However, it has become clear that although these tests are very useful, neuropeptides have distinct behavioral effects and dose-dependent characteristics, and therefore, use of these tests with neuropeptides must be done with an understanding of their unique characteristics. This review will focus on the behavioral actions of neuropeptides and their synthetic analogs, particularly in studies utilizing various preclinical tests of depression and anxiety. Specifically, the following neuropeptide systems will be reviewed: corticotropin-releasing factor (CRF), urocortin (Ucn), teneurin C-terminal associated peptide (TCAP), neuropeptide Y (NPY), arginine vasopressin (AVP), oxytocin, the Tyr-MIF-1 family, cholecystokinin (CCK), galanin, and substance P. These neuropeptide systems each have a unique role in the regulation of stress-like behavior, and therefore provide intriguing therapeutic targets for mood disorder treatment. Copyright (c) 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20026211     DOI: 10.1016/j.peptides.2009.12.015

Source DB:  PubMed          Journal:  Peptides        ISSN: 0196-9781            Impact factor:   3.750


  65 in total

1.  Variation in maternal and anxiety-like behavior associated with discrete patterns of oxytocin and vasopressin 1a receptor density in the lateral septum.

Authors:  J P Curley; C L Jensen; B Franks; F A Champagne
Journal:  Horm Behav       Date:  2012-01-28       Impact factor: 3.587

2.  Interleukin-15 affects serotonin system and exerts antidepressive effects through IL15Rα receptor.

Authors:  Xiaojun Wu; Hung Hsuchou; Abba J Kastin; Yi He; Reas S Khan; Kirsten P Stone; Michael S Cash; Weihong Pan
Journal:  Psychoneuroendocrinology       Date:  2010-08-17       Impact factor: 4.905

Review 3.  Exercise offers anxiolytic potential: a role for stress and brain noradrenergic-galaninergic mechanisms.

Authors:  Natale R Sciolino; Philip V Holmes
Journal:  Neurosci Biobehav Rev       Date:  2012-07-05       Impact factor: 8.989

4.  Effects of early life social stress on maternal behavior and neuroendocrinology.

Authors:  Christopher A Murgatroyd; Benjamin C Nephew
Journal:  Psychoneuroendocrinology       Date:  2012-07-07       Impact factor: 4.905

Review 5.  PLASMA OXYTOCIN CONCENTRATION AND DEPRESSIVE SYMPTOMS: A REVIEW OF CURRENT EVIDENCE AND DIRECTIONS FOR FUTURE RESEARCH.

Authors:  Suena H Massey; Katherine A Backes; Stephanie A Schuette
Journal:  Depress Anxiety       Date:  2016-01-12       Impact factor: 6.505

6.  Cholecystokinin knock-down in the basolateral amygdala has anxiolytic and antidepressant-like effects in mice.

Authors:  C Del Boca; P E Lutz; J Le Merrer; P Koebel; B L Kieffer
Journal:  Neuroscience       Date:  2012-05-18       Impact factor: 3.590

Review 7.  The role of oxytocin in psychiatric disorders: a review of biological and therapeutic research findings.

Authors:  David M Cochran; Daniel Fallon; Michael Hill; Jean A Frazier
Journal:  Harv Rev Psychiatry       Date:  2013 Sep-Oct       Impact factor: 3.732

Review 8.  Role of orexin in the pathophysiology of depression: potential for pharmacological intervention.

Authors:  Mathieu Nollet; Samuel Leman
Journal:  CNS Drugs       Date:  2013-06       Impact factor: 5.749

Review 9.  Oxytocin and Anxiety Disorders: Translational and Therapeutic Aspects.

Authors:  Wadih Jean Naja; Michaelangelo Pietro Aoun
Journal:  Curr Psychiatry Rep       Date:  2017-08-15       Impact factor: 5.285

10.  Neuropeptidergic signaling partitions arousal behaviors in zebrafish.

Authors:  Ian G Woods; David Schoppik; Veronica J Shi; Steven Zimmerman; Haley A Coleman; Joel Greenwood; Edward R Soucy; Alexander F Schier
Journal:  J Neurosci       Date:  2014-02-26       Impact factor: 6.167

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.